For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BAVARIAN NORDIC (BVNRY - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BAVARIAN NORDIC is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BVNRY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BVNRY's full-year earnings has moved 7.41% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BVNRY has moved about 22.90% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 1.63% on average. This means that BAVARIAN NORDIC is performing better than its sector in terms of year-to-date returns.
To break things down more, BVNRY belongs to the Medical - Biomedical and Genetics industry, a group that includes 381 individual companies and currently sits at #39 in the Zacks Industry Rank. On average, stocks in this group have gained 8.58% this year, meaning that BVNRY is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BVNRY. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BAVARIAN NORDIC (BVNRY - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BAVARIAN NORDIC is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BVNRY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BVNRY's full-year earnings has moved 7.41% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BVNRY has moved about 22.90% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 1.63% on average. This means that BAVARIAN NORDIC is performing better than its sector in terms of year-to-date returns.
To break things down more, BVNRY belongs to the Medical - Biomedical and Genetics industry, a group that includes 381 individual companies and currently sits at #39 in the Zacks Industry Rank. On average, stocks in this group have gained 8.58% this year, meaning that BVNRY is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BVNRY. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BVNRY - FREE